Abstract:Introduction Vulvar lichen sclerosus (VLS) is a chronic inflammatory skin condition that is a leading cause of sexual dysfunction. VLS skin becomes fragile, thickened, and extremely itchy. As disease advances, scarring of the vulva, resorption of the labia and clitoris, or even cancer can occur. VLS makes sexual intercourse painful and greatly impairs quality of life. Despite impacting millions of patients, VLS remains poorly understood and is underrepresented in education and research. Current treatments are effective at managing the symptoms but do not target or reverse the underlying disease. To reduce the morbidity and mortality associated with this condition, early diagnostics and targeted therapeutics are desperately needed. Inflammation and scarring are distinguishing factors, but how these processes interact remains unknown. Fibroblasts are a class of cells responsible for producing extracellular matrix (ECM) and inflammatory cytokines, and we have established a cell-based model of disease to investigate their role in VLS further. We hypothesize that fibroblasts are key modulators in mechanism by coordinating inflammatory and fibrotic responses in VLS. Objective We aim to elucidate the role of fibroblasts in driving inflammation and fibrosis in VLS with the goal of identifying disease-specific biomarkers. Methods 6 mm punch biopsies of vulvar skin were collected from eight VLS patients and six healthy individuals. For VLS cases, biopsies of visibly affected and unaffected areas were collected for within-patient comparisons. Biopsies were cut in half to analyze vulvar skin gene expression and to establish primary human fibroblasts. Cells were treated with transforming growth factor beta (TGF-β) to stimulate scarring and inflammatory pathways. Production of cytokines and ECM materials was assessed utilizing quantitative polymerase chain reaction (qPCR), western blot, and enzyme-linked immunosorbent assay (ELISA) techniques. Data analysis was conducted using ANOVA and t-tests, and the threshold for significance was p<0.05. Results When stimulated with TGF-β, fibroblasts cultured from VLS scars produce significantly more α-smooth muscle actin (α-SMA) and downstream signaling proteins (phospho-SMAD2) compared to cells grown from unscarred areas. In addition, production of ECM components such as collagen, fibronectin, and calponin is dysregulated. However, compared to cells cultured from healthy vulvar skin, VLS fibroblasts produce significantly more pro-inflammatory cytokines, such as interleukin 6 (IL-6) and interleukin 8 (IL-8), even at baseline. Conclusions Inflammation and fibrosis lead to irreversible changes in VLS, but how this occurs is poorly elucidated. Fibroblasts are likely key contributors, responding to TGF-β to activate downstream signaling pathways that result in myofibroblast activation, accumulation of ECM, and excessive production of cytokines. IL-8 in particular, a neutrophil chemokine, is perpetually high in VLS fibroblasts, which may serve to recruit immune cells to fibrotic areas. Further investigation into the interplay and order of these molecular events is needed to understand the progression of this disease and to identify improved targets for therapeutics. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: SPM Therapeutics.

Patient satisfaction and sexual issues in vulvar lichen sclerosus treatment: a monocentric certified dysplasia unit survey analysis

Self-perceived Burden, Impairment in Quality of Life and Sexual Functioning, and Further Implications in Patients with Vulvar Lichen Sclerosus: A Narrative Review and Personal Experience

A systematic review of outcome measures evaluating treatment efficacy in vulval lichen sclerosus and evaluation of patients' priorities

Evaluation of the therapeutic effects of Photodynamic Therapy in vulvar lichen sclerosus and impact on patient quality of life and sexual funtion

The Barriers and Perceived Benefits to Vulvar Self-examination in the Management of Vulvar Lichen Sclerosus

A Longitudinal Multiinstitutional Study of Vulvar Lichen Sclerosus: From Childhood to Perimenopause

P078 Establishing diagnostic criteria for vulval lichen sclerosus (SHELLS): an international electronic-Delphi consensus study

The treatment of vulvar lichen sclerosus and female sexual dysfunction

The Prevalence of Self-Reported Medical Comorbidities in Patients with Vulvar Lichen Sclerosus: A Single-Center Retrospective Study

Searching for a “Window of Opportunity” in the Treatment of Vulvar Lichen Sclerosus: Evidence for Therapeutic Benefits of an Early Corticosteroid Treatment

Navigating Sex Hormone Dynamics and Pioneering Personalized Treatment Paradigm

(103) The Crossroads Of Inflammation And Scarring In Vulvar Lichen Sclerosus

Monitoring adherence to vulvar lichen sclerosus treatment – a prospective study

Single-cell and spatial transcriptomics of vulvar lichen sclerosus reveal multi-compartmental alterations in gene expression and signaling cross-talk

Assessment of the Cutaneous Hormone Landscapes and Microbiomes in Vulvar Lichen Sclerosus

Efficacy of photodynamic therapy in vulvar lichen sclerosus treatment based on immunohistochemical analysis of CD34, CD44, myelin basic protein, and Ki67 antibodies

5-Aminolevulinic acid photodynamic therapy is a safe and effective treatment for female patients with intractable vulvar lichen sclerosus

Fractional CO𝟐 Laser Therapy for Vulvar Lichen Sclerosus in Adults

Vulvar lichen sclerosus in girls and adult females: A single-center retrospective study of 744 patients in China

Treatment-induced anogenital melanosis is a very frequent finding in patients with vulvar lichen sclerosus